Skip to main content
Premium Trial:

Request an Annual Quote

Caprion Collaborating with G3 on Biomarkers for Cardiovascular Disease

NEW YORK (GenomeWeb News) – Global Genomics Group and Caprion Proteomics said today that they have entered into a collaboration to investigate potential biomarkers and pharmaceutical targets for cardiovascular disease.

Under the agreement, Caprion will identify blood-based protein markers for the ongoing GLOBAL (Genetic Loci and Burden of Atherosclerotic Lesions) study, a multi-center pan-omic study that aims to recruit up to 10,000 patients to characterize disease pathways and biomarkers linked to coronary artery disease.

The GLOBAL study combines genomics, epigenomics, transcriptomics, proteomics, metabolomics, lipidomics, and lipoprotein proteomics with coronary computed tomographic angiography data. Caprion will generate proteomic data for the effort using its CellCarta system, a mass spec-based platform for measuring differences in protein expression between plasma samples.

"Caprion's unbiased and targeted mass spectrometry-based proteomic platform will provide an in-depth assessment of plasma proteins to complement the other 'omic' approaches we are using in the GLOBAL study," G3 CEO Szilard Voros said in a statement.

G3 is funding the GLOBAL study and conducting it with its strategic partner, Health Diagnostic Laboratory.

Financial and other terms of the agreement were not disclosed.